Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rilzabrutinib versus placebo in persistent or chronic immune thrombocytopenia
2020-002063-60Phase 3Active
- Sponsor
- Principia Biopharma
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Rilzabrutinib with Placebo (2 arms). Primary endpoint: Durable platelet response. Started Oct 2020; status: active.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2020-002063-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002063-60.